Nortech Systems Inc.
NSYS
Nortech Systems Inc.
Energy Small Cap Updated Mar 13, 2026

Nortech did $128M in annual revenue and still lost $0.47 a share in 2024.

If you own NSYS, you own a tiny manufacturer with real sales and almost no room for mistakes.

$9.50
Market cap ~$26M · 52-week range $6–$12
19
Composite
Our overall rating — combines growth, value, risk, and momentum
19
/ 100

Weak

Combines growth, value, risk, and momentum factors into a single institutional-grade score.

What it is
Nortech builds complex electronic parts and assemblies for medical, defense, and industrial customers.
How it gets paid
Last year Nortech Systems made $128M in revenue. Printed circuit board assemblies was the main engine at $38M, or 30% of sales.
What just happened
Revenue hit $88M, but EPS still landed at -$0.41.
C balance sheet — red flag territory — real financial stress
10/100 earnings predictability — expect surprises
17.2% return on capital — nothing to write home about
-$0.47 fy2024 eps est
$128M fy2024 rev est
XVARY composite: 19/100 — weak
Nortech builds complex electronic parts and assemblies for medical, defense, and industrial customers.
This is a small company that does annoying, hard-to-switch work. If your product needs cables, circuit boards, testing, and final assembly, moving suppliers can delay shipments and create fresh certification headaches. Nortech spreads that work across 7 facilities and 701 employees, which gives customers one vendor instead of a relay race.
energy microcap contract-manufacturing medical-devices defense-supply-chain
$128M annual revenue
Printed circuit board assemblies
$38M
+4.4%
Wire and cable assemblies
$30M
+3.0%
Electromechanical box builds
$24M
+4.4%
Engineering, testing, and prototyping
$18M
+3.0%
Supply chain and post-market services
$18M
+3.0%
Cables and wiring assemblies
Complex Interconnect Solutions
part of a $128M revenue base
these assemblies sit inside the core manufacturing operation, and the whole company only kept 14.7% gross margin. that tells you pricing power is thin.
mid-teen margin
Circuit board manufacturing
Printed Circuit Board Assemblies
medical and defense exposure
the boards are more technical than basic assembly work, but the business still ran at a -0.5% operating margin. complexity has not translated into clean profitability yet.
-0.5% operating margin
Design and technical services
Value-Added Engineering
supports a $64M medical segment
this is the part meant to keep Nortech from being just another assembler. the problem is simple: $64M of medical revenue still sits inside a company that needed a credit waiver.
differentiation attempt
23%
debt load
Long-term debt is 23% of capital. Plain English: about a quarter of the funding stack is borrowed money, which matters more when operating margin is only 1.6%.
1.6%
operating margin
Jargon: operating margin → profit after core business costs → so what: on $128M of sales, Nortech kept only about $2.0M before interest and taxes.
17.2%
return on capital
Jargon: return on capital → profit earned on the money used in the business → so what: the assets can produce decent returns when operations are steady.
$8M
long-term debt
Against a market cap near $26M, $8M of debt is real. Deadpan version: lenders have a claim on almost a third of what the stock market says this company is worth.
C
Strength
  • balance sheet grade C — very weak — significant financial distress
  • risk rank 5 — safer than 5% of stocks
  • price stability 10 / 100
  • long-term debt $8M (23% of capital)
C — below average. watch for debt servicing and cash burn.
source: institutional data · return history unavailable
missed estimates
Revenue hit $88M, but EPS still landed at -$0.41.
Sales surged 189% vs. prior year, yet gross margin was only 14.7%. More volume helped the top line, but the bottom line still looked like a leak.
$32M
revenue
$0.41
eps
14.7%
gross margin
the number that mattered
14.7% gross margin mattered most because a contract manufacturer with thin margins can add a lot of revenue without creating much profit.
source: company earnings report, 2026

Get this snapshot in your inbox

This page, delivered free — plus weekly updates when the numbers change. Plain English, no spam.

Weekly updates Earnings alerts Plain English No spam

The #1 risk is another lender problem tied to the Feb. 27, 2026 credit waiver. this is not abstract balance-sheet theory. it already happened once.

!
High
Credit covenant pressure
Nortech defaulted on its credit agreement and entered a waiver and amendment on Feb 27, 2026. That tells you the capital structure is now part of the operating story.
Impact: if lender terms tighten again, even a business with only $8M of long-term debt can lose flexibility fast because margins are already thin.
!
High
Chronic unprofitability
Trailing 12-month net margin is -2.25%, and the recent operating margin was -0.5%. A manufacturer keeping only 14.7% gross margin does not have much room for cost misses.
Impact: all $128M of revenue is exposed to execution slippage when the profit buffer is this thin.
Med
Medical customer concentration
Medical accounts for $64M, or half the business. That is a stabilizer if demand holds. It becomes a problem fast if a key program slips or a large customer leaves.
Impact: a stumble in the largest segment would hit both revenue and factory utilization at the same time.
Med
Institutional retreat
Institutions own just 3.05% of the stock, and holdings fell 21.47% last quarter. This is not deep sponsorship.
Impact: when ownership is this light, small-cap volatility gets amplified because there are fewer patient holders to catch the tape.
you own a manufacturer that lost money on $128M of sales and already needed a waiver from its lender. that combination does not leave much room for another bad quarter.
Source: institutional data · regulatory filings · risk analysis
Credit
Any update to the waiver language
The waiver on Feb 27, 2026 is the live wire. If your next filing still reads like a lender negotiation, the turnaround has not earned much trust.
Margin
Gross margin holding above 14.7%
This is the first number to watch. With operating margin already at -0.5%, even a small gross-margin slip can wipe out the restructuring story.
Earnings
Q4 2025 and FY2025 results
You want two things from the next report: cleaner profitability and plain disclosure on lender terms. If you do not get both, the market will keep pricing stress first.
Customer mix
Medical staying near $64M of the revenue base
Medical is half the business. If that segment weakens while aerospace and industrial stay at $32M each, the diversification story gets a lot less comforting.
earnings predictability
10 / 100
in human-speak, forecasts deserve a discount because the business is thin-margin, loss-making, and now dealing with lender pressure.
price stability
10 / 100
this stock does not trade like a calm industrial. it trades like a small cap where every filing can reset the story.
Source: institutional data

institutional ownership data for NSYS is being compiled.

Source: institutional data
3-5 year target range
$10 Current price
Target midpoint · from current
target data not available

Want the deeper analysis?

The full deep dive: DCF model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.

See plans from $5/mo
NSYS
XVARY Deep Dive
nsys
The full analysis is in the works.
What you'll get
DCF valuation model
Bull / base / bear scenarios
Competitive moat breakdown
Quarterly earnings tracker
Operating model projections
Risk matrix with kill criteria
Original price target + conviction
Updated with every earnings
Free · no spam · you'll be first to read it